Tumor Treatment

Tumor Treatment

LiquidHALLMARK®


Our flagship blood test that simultaneously detects cancer-causing gene mutations and viruses for multiple cancers to improve cancer diagnosis and treatment selection.

Cancer
Type
···
Sample
Type
···
Turnaround
Time
···
Multiple Cancers Blood 7-10 Days

LiquidHALLMARK® is the world’s first sequencing test that detects multiple cancer-causing gene mutations and viruses from circulating tumor DNA in blood. The test detects clinically relevant mutations in multiple cancers including breast, colon, lung and nasopharyngeal cancers, among others, in one single test. It covers microsatellite instability (MSI) and cancer-associated viruses such as the Epstein-Barr virus (EBV). The test is based on Lucence’s core molecular watermarking technology AmpliMARK™ for accurate and ultra-deep sequencing results.

Benefits:

  • Non-invasive. Requires one draw of blood
  • Provide actionable clinical information
  • > 99% sensitivity and specificity
  • Customized to detect Asian cancers

Recommended For:

  • Patients with advanced or late stage cancers
  • Patients who have tested negative for single gene mutations and require more comprehensive tumor profiling.
  • Patients with cancers of unknown primary origins
  • Patients with inadequate amount of tissue or unobtainable tissue for tissue biopsy
  • Patients who may prefer non-invasive testing or are not suitable for invasive surgical procedure
Target List
Genes
AKT1 ALK# APC AR BRAF CDKN2A
CTNNB1 EGFR ERBB2 (HER2)# ESR1 GNAS KIT
KRAS MED12 MET# NRAS PIK3CA PTEN
SMAD4^ TP53^ VHL
MSI
BAT25 BAT26 NR21 NR24 NR27 MONO27
Viral Targets
EBV BamHI-W EBV EBNA1

LiquidMARK


LiquidMARK™ is a subset of individual blood tests under LiquidHALLMARK® for breast, colon and lung cancers.

Gene List
Tests Targets Turnaround Time
LiquidMARK™ Breast Genes*: ERBB2 (HER2)#, ESR1, PIK3CA
MSI: BAT25, BAT26, NR21, NR24, NR27, MONO27
7-10 days
LiquidMARK™ Colon Genes*: BRAF V600, ERBB2 (HER2)#, KRAS, NRAS
MSI: BAT25, BAT26, NR21, NR24, NR27, MONO27
7-10 days
LiquidMARK™ Lung Genes*: ALK#, BRAF V600, EGFR, ERBB2 (HER2)#, MET#
MSI: BAT25, BAT26, NR21, NR24, NR27, MONO27
7-10 days

 


* Targeted regions selected to maximize detection of known hotspot mutations. List available on request.
# Detection of genetic variants and amplification.
^ Full coverage.

References:
1. Choudhury, Y. et al. Journal of Clinical Oncology, 36, 2018 (suppl; abstr e24107)
2. Vo, J. H. et al., Scientific Reports, 6:13 (2016)
3. Tan, M.H. and Vo, J. H. Patent Cooperation Treaty Application No. PCT/SG2016/050611 (2016)
4. Choudhury, Y., Chen, H. and Tan, M. H. Singapore Patent Application No. 10201805450Y (2018)

LiquidSCREEN™ & LiquidTRACK


Blood tests that detect and track specific cancer mutations in the tumor for cancer diagnosis and treatment.

 

Cancer
Type
···
Sample
Type
···
Turnaround
Time
···
Colon, Lung and
Pancreatic Cancers
Blood and
Cerebrospinal Fluid
(CSF)
2 Days

LiquidSCREEN™ and LiquidTRACK™ are liquid biopsy tests that detects specific cancer mutations from circulating tumor DNA in blood. The tests help physicians select targeted therapies and monitor treatment response based on the cancer driving mutation. Based on our proprietary technology, the tests detect quantitative level of mutation present in the blood, allowing for more accurate disease monitoring and trending. The technology has been clinically validated in a multicentre Singapore study.

LiquidSCREEN™

  • Patient: Has not done liquid biopsy before
  • Objective: To detect cancer driving mutation
    for treatment selection LiquidSCREEN™

LiquidTRACK™

  • Patient: Has done LiquidSCREEN™ and identified
    the sensitizing and resistance mutation
  • Objective: To monitor and detect resistance to
    treatment

Benefits:

  • Simple and non-invasive. One draw is all it takes
  • Test results back in 2 working days for rapid decision making
  • Ultrasensitive with detection limits of up to 0.01%

Recommended For:

  • Patients with advanced or late stage cancers
  • Patients with inadequate amount of tissue or unobtainable tissue for tissue biopsy
  • Patients who may prefer non-invasive testing or are not suitable for invasive surgical procedure
Gene List
Tests Genes Sequenced Turnaround Time
LiquidSCREEN™ Lung Exon 18: G719A, G719C, G719S
Exon 19: delE746-A750, delL747-P753insS, delL747-A750insP, delL747-T751
Exon 20: T790M
Exon 21: L858R, L861Q
2 days
LiquidTRACK™ Lung EGFR: Selected patient-matched sensitizing mutation, T790M and C797S 2 days
LiquidSCREEN™ Colon KRAS: G12A, G12C, G12D, G12R, G12S, G12V, G13D, Q61H 2 days
LiquidTRACK™ Colon KRAS: patient matched mutation 2 days
LiquidSCREEN™ Pancreas KRAS: G12A, G12C, G12D, G12R, G12S, G12V, G13D, Q61H 2 days
LiquidTRACK™ Pancreas KRAS: patient matched mutation 2 days

Bundled EXPRESS Service

Order both LiquidSCREEN™ Lung + LiquidMARK™ Lung
to get faster turnaround time

LiquidSCREEN™ Lung

1 day (instead of 2 days)

LiquidMARK™ Lung

7-10 days


References:
1. Luo, J. et al. A Systematic Review and Meta-Analysis, Science Reports, 4: 6269, 2014.
2. Kobayashi, S. et al. The New English Journal of Medicine, 352(8):786-792, 2005.
3. Janne, PA. et al. The New English Journal of Medicine, 372(18), 1689-1699, 2015.
4. Shi, J. et al. Annals of Oncology, Volume 28, Issue suppl_5, 2017.

LumiBRCA™ & LumiTHERA


Companion diagnostic tests that detect specific genetic mutations in breast or ovarian cancers for targeted cancer treatment.

Cancer
Type
···
Sample
Type
···
Turnaround
Time
···
Breast and
Ovarian Cancers
Blood 2-3 Weeks

LumiBRCA™ and LumiTHERA™ are blood tests that detects BRCA and other genetic mutations associated with breast and ovarian cancers for targeted treatment selection.

In addition to our specialized sequencing, our tests also include multiplex ligation-dependent probe amplification (MLPA) screening. MLPA allows us to detect large genomic rearrangements in BRCA genes, which contributes 11-36% of all BRCA genetic variants. The tests will help physicians to decide whether a patient is suitable for an FDA-approved targeted therapy called PARP inhibitor and immunotherapy for treatment of breast and ovarian cancers.

What is the difference between
LumiBRCA™ and LumiTHERA™?

LumiBRCA™ tests for mutations involving the BRCA genes together with mutations arising from large genomic rearrangements to check if the patient’s tumor is suitable for PARP inhibitor therapy.

LumiTHERA™ is an expanded version of LumiBRCA™ that includes the genes involved with the mismatch repair function to check if the patient’s tumor is suitable for both PARP inhibitor therapy and immunotherapy.

Benefits:

  • Non-Invasive. One draw of blood for diagnosis
  • Complete coverage of entire coding sequences of BRCA1
    and BRCA2
  • Close to 100% sensitivity and specificity
  • Cancer genetics counsellor at Lucence available for
    discussion with the ordering physician for optimal
    diagnosis and management

Recommended For:

  • Patients diagnosed with breast and/or ovarian cancers
GENES
LumiBRCA™
LumiTHERA™
ATM
BRCA1
BRCA2
BRIP1
CHEK2
EPCAM
MLH1
MSH2
MSH6
MUTYH
NBN
PALB2
PMS2
PTEN
RAD51C
RAD51D

References:
1. FDA grants accelerated approval to new treatment for advanced ovarian cancer (2016)
2. European Medicines Agency (2015)
3. Alsop, K. et al. J Clin Oncol. 30, 2654-2663, 2012
4. Moller, P. et al. Eur J Cancer, 43, 1713-1717, 2007 5. Zhang, S. et al. Gynecol. Oncol. 121, 353-357, 2011
5. Casilli et al. J Med Genet, 43(9):e49, 2006
6. Eccles, D. M. et al. Adv. Ther. 33, 129-150, 2016
7. Sluiter & Rensburg, Breast Cancer Res Treat. 125(2):325-49, 2011
8. AstraZenaca Press Release: Lynparza meets primary endpoint in Phase III trial in BRCA-mutated metastatic breast cancer (2017)


A molecular tissue test to distinguish breast fibroadenoma, the world's most common tumor, from phyllodes tumor.

Sample Type
···
Turnaround Time
···
FFPE 2-3 Weeks

FibroPhyllo™ Tissue is the first 5-gene panel assay to distinguish fibroadenomas from phyllodes tumors. Fibroadenoma is the most common breast tumor in the world. Phyllodes tumor is a less common tumor that can be malignant; it can also recur even after being removed. It can be challenging to differentiate between the two types of breast tumors because they share overlapping clinical and histological features. Current immunohistochemical techniques are subjective and open to interpretation.

We have identified 5 genes that can accurately differentiate between the two type of tumors for better surgical decision-making. This technology has been clinically validated in a study with Singapore General Hospital.

U.S. National Comprehensive Cancer Network (NCCN) 2018 Guidelines:
  • Fibroadenomas: Simple excision without tumor-free tissue
  • Phyllodes tumors: Wide surgical excision with tumor-free margins of 1 cm or more

Benefits:

  • Assists pathologists with refining the histological diagnosis of breast lumps.
  • Improves surgical decision-making.
  • Reduces over- or under- treatment of patients

Recommended For:

  • Patients who want to make the right surgical decision about their breast lumps

References:
1. Tan, B.Y. and Tan, P.H. Surgical Pathology Clinics 11(1):17-42 (2018).
2. Tan, B.Y. et al. Histopathology 68(1): 5-21 (2016).
3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Breast Cancer Version 1.2018.
4. Tan, M. H., Tan, P. H., Tan, W. J., Cima, I. Patent Cooperation Treaty Application No. PCT/SG2016/050117
5. Tan, W. J. et al. Breast Cancer Res 18:31; 1-9 (2016)

To order our tests, please call or email us. Our customer care team will assist you on the ordering process.



Need Help?